{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:21:37Z","timestamp":1774084897681,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.clinthera.2016.05.008","type":"journal-article","created":{"date-parts":[[2016,6,8]],"date-time":"2016-06-08T17:05:06Z","timestamp":1465405506000},"page":"1726-1737.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effect of Gabapentin Enacarbil on Individual Items of the International Restless Legs Study Group Rating Scale and Post-sleep Questionnaire in Adults with Moderate-to-Severe Primary Restless Legs Syndrome: Pooled Analysis of 3 Randomized Trials"],"prefix":"10.1016","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct00298623","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00365352","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01332305","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Mansoor","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Hays","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Steven Poceta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Jaros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwendoline","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.05.008_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1389-9457(03)00010-8","article-title":"Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health","volume":"4","author":"Allen","year":"2003","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.05.008_bib2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.sleep.2013.05.016","article-title":"The long-term treatment of restless legs syndrome\/Willis-Ekbom disease: evidence based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group","volume":"14","author":"Garcia-Borreguero","year":"2013","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.05.008_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/mds.870120111","article-title":"Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria","volume":"12","author":"Montplaisir","year":"1997","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2016.05.008_bib4","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archinte.165.11.1286","article-title":"Restless legs syndrome prevalence and impact: REST general population study","volume":"165","author":"Allen","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2016.05.008_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.sleep.2004.03.006","article-title":"Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study","volume":"5","author":"Hening","year":"2004","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.05.008_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.sleep.2009.03.007","article-title":"Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: prevalence and characteristics","volume":"11","author":"Allen","year":"2010","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.05.008_bib7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/mds.23430","article-title":"Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States","volume":"26","author":"Allen","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2016.05.008_bib8","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.sleep.2010.12.018","article-title":"Prevalence of restless legs syndrome in North American and Western European populations: a systematic review","volume":"12","author":"Innes","year":"2011","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.05.008_bib9","unstructured":"Willis-Ekbom Disease (WED) Foundation Patient Odyssey Survey, 2013. http:\/\/rls.org\/file\/documents\/WEDF-RLS-Patient-Survey-Summary-Part-2.pdf. Accessed September 30, 2014."},{"key":"10.1016\/j.clinthera.2016.05.008_bib10","unstructured":"Ondo WG, Becker P. Willis-Ekbom disease\/restless legs syndrome significantly impacts patients\u2019 sleep, activities, and emotional health: results of the \u201cPatient Odyssey\u201d survey. Presented at SLEEP 2014; Minneapolis, MN; May 31\u2013June 4, 2014. Abstract 0639."},{"key":"10.1016\/j.clinthera.2016.05.008_bib11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2377-11-28","article-title":"Algorithms for the diagnosis and treatment of restless legs syndrome in primary care","volume":"11","author":"Garcia-Borreguero","year":"2011","journal-title":"BMC Neurol"},{"key":"10.1016\/j.clinthera.2016.05.008_bib12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00406-006-0684-0","article-title":"High prevalence of restless legs syndrome in somatoform pain disorder","volume":"257","author":"Aigner","year":"2007","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.clinthera.2016.05.008_bib13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.sleep.2012.08.013","article-title":"Painful polyneuropathy associated with restless legs syndrome. Clinical features and sensory profile","volume":"14","author":"Gemignani","year":"2013","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.05.008_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1389-9457(02)00258-7","article-title":"Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome","volume":"4","author":"Walters","year":"2003","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.05.008_bib15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/mdc3.12088","article-title":"Review of severity rating scales for restless legs syndrome: critique and recommendations","volume":"1","author":"Walters","year":"2014","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.clinthera.2016.05.008_bib16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1124\/jpet.104.067959","article-title":"XP13512 [(+\/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II: improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys","volume":"311","author":"Cundy","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2016.05.008_bib17","unstructured":"HORIZANT US [2013 prescribing information]. http:\/\/www.horizant.com\/assets\/docs\/Horizant_PrescribingInformation.pdf. Accessed September 30, 2014."},{"key":"10.1016\/j.clinthera.2016.05.008_bib18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1212\/01.wnl.0000341770.91926.cc","article-title":"XP052 Study Group. Randomized, double-blind, placebo-controlled study of XP13512\/GSK1838262 in patients with RLS","volume":"72","author":"Kushida","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2016.05.008_bib19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/jcm7090282","article-title":"A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome","volume":"7","author":"Lee","year":"2011","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.clinthera.2016.05.008_bib20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/WNF.0b013e318259eac8","article-title":"A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome","volume":"35","author":"Lal","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2016.05.008_bib21","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2165\/11634870-000000000-00000","article-title":"Dose response of gabapentin enacarbil versus placebo in subjects with moderate-to-severe primary restless legs syndrome: an integrated analysis of three 12-week studies","volume":"26","author":"VanMeter","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2016.05.008_bib22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2377-11-48","article-title":"Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials","volume":"11","author":"Canafax","year":"2011","journal-title":"BMC Neurol"},{"key":"10.1016\/j.clinthera.2016.05.008_bib23","series-title":"Statistics without maths for psychology using SPSS for Windows","year":"2004"},{"key":"10.1016\/j.clinthera.2016.05.008_bib24","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.sleep.2014.03.025","article-title":"Restless legs syndrome\/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria\u2013history, rationale, description, and significance","volume":"15","author":"Allen","year":"2014","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.05.008_bib25","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/mds.1209","article-title":"Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms","volume":"16","author":"Ulfberg","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2016.05.008_bib26","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/sleep\/32.6.772","article-title":"Polysomnographic and health-related quality of life correlates of restless legs syndrome in the Sleep Heart Health Study","volume":"32","author":"Winkelman","year":"2009","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.05.008_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/JPRLS.S40804","article-title":"Gabapentin enacarbil in subjects with moderate to severe primary restless legs syndrome with and without severe sleep disturbance: an integrated analysis of subjective and novel sleep endpoints from two studies","volume":"3","author":"Bogan","year":"2013","journal-title":"J Parkinsonism Restless Legs Syndrome"},{"key":"10.1016\/j.clinthera.2016.05.008_bib28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.sleep.2004.07.006","article-title":"Psychometric properties of the Medical Outcomes Study Sleep measure","volume":"6","author":"Hays","year":"2005","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.05.008_bib29","doi-asserted-by":"crossref","first-page":"512","DOI":"10.4065\/mcp.2009.0700","article-title":"Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study","volume":"85","author":"Bogan","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2016.05.008_bib30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.pnpbp.2011.10.009","article-title":"Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients","volume":"36","author":"Inoue","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2016.05.008_bib31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/sleep\/32.2.159","article-title":"A randomized, double-blind, placebo-controlled, crossover study of XP13512\/GSK1838262 in the treatment of patients with primary restless legs syndrome","volume":"32","author":"Kushida","year":"2009","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.05.008_bib32","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/mds.23771","article-title":"Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome","volume":"26","author":"Winkelman","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2016.05.008_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sleep.2003.07.005","article-title":"Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS)","volume":"5","author":"Winkelman","year":"2004","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.05.008_bib34","first-page":"81","article-title":"Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study","volume":"33","author":"Cornelius","year":"2010","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.05.008_bib35","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.sleep.2011.03.003","article-title":"Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample","volume":"12","author":"Allen","year":"2011","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.05.008_bib36","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.mayocp.2013.06.016","article-title":"Medical Advisory Board of the Willis-Ekbom Disease Foundation. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome","volume":"88","author":"Silber","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2016.05.008_bib37","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/brain\/awm244","article-title":"Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies","volume":"131","author":"Fulda","year":"2008","journal-title":"Brain"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0149291816303423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0149291816303423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T07:32:28Z","timestamp":1568014348000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816303423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0149291816303423"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.05.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Gabapentin Enacarbil on Individual Items of the International Restless Legs Study Group Rating Scale and Post-sleep Questionnaire in Adults with Moderate-to-Severe Primary Restless Legs Syndrome: Pooled Analysis of 3 Randomized Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.clinthera.2016.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}